Fentanyl-related deaths in Ontario, Canada: Toxicological findings and circumstances of death in 112 cases (2002-2004)

Journal of Analytical Toxicology

Volumn 30, Issue 8, 2006, Pages 603-610

  Martin, Teri L ^a   Woodall, Karen L ^a   McLellan, Barry A ^b  

^a Ministry of Community Safety and Correctional Services Centre of Forensic Sciences   (Canada)

^b Ministry of Community Safety and Correctional Services   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOPSY; CANADA; CHILD; CONTROLLED STUDY; DEATH; DRUG BLOOD LEVEL; DRUG INTOXICATION; FEMALE; HUMAN; MALE;

EID: 33750170409     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/30.8.603     Document Type: Article

References (29)

1. R. Kronstrand, H. Druid, P. Holmgren, and J. Rajs. A cluster of fentanyl-related deaths among drug addicts in Sweden. Forensic Sci. Int. 88(3): 185-195 (1997).
2. G.L. Henderson. Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. J. Forensic Sci. 36(2): 422-433 (1991).
3. D.T. Anderson and J.J. Muto. Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25 cases. J. Anal. Toxicol. 24(7): 627-634 (2000).
4. J.J. Kuhlman, Jr., R. McCaulley, T.J. Valouch, and G.S. Behonick. Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J. Anal. Toxicol. 27(7): 499-504 (2003).
5. P.K. Lelleng, L.I. Mehlum, L. Bachs, and I. Morild. Deaths after intravenous misuse of transdermal fentanyl. J. Forensic Sci. 49(6): 1364-1366 (2004).
6. A. Tharp, R.E. Winecker, and D.C. Winston. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am. J. Forensic Med. Pathol. 25(2): 178-181 (2004).
7. M.D. Reeves and C.J. Ginifer. Fatal intravenous misuse of transdermal fentanyl. Med. J. Aust. 177: 552-553 (2002).
8. I.A. Liappas, N.P. Dimopoulos, E. Mellos, O.E. Gitsa, A.I. Liappas, and A.D. Rabavilas. Oral transmucosal abuse of transdermal fentanyl. J. Psychopharmacol. 18(2): 277-280 (2004).
9. M.L. Arvanitis and R.C. Satonik. Transdermal fentanyl abuse and misuse. Am. J. Emerg. Med. 20(1): 58-59 (2002).
10. C. Kramer and M. Tawney. A fatal overdose of transdermally administered fentanyl. J. Am. Osteopath Assoc. 98(7): 385-386 (1998).
11. T.P. Coon, M. Miller, D. Kaylor, and K. Jones-Spangle. Rectal insertion of fentanyl patches: a new route of toxicity. Ann. Emerg. Med. 46(5): 473 (2005).
12. K.A. Marquardt and R.S. Tharratt. Inhalation abuse of fentanyl patch. J. Toxicol. Clin. Toxicol. 32(1): 75-78 (1994).
13. J.E. Eckenhoff and S.R. Oech. The effects of narcotics and antagonists upon respiration and circulation in man: a review. Clin. Pharmacol. Ther. 1(4): 483-524 (1960).
14. B. Raymond and I. Morawiecka. Transdermal fentanyl (Duragesic): respiratory arrest in adolescents. Canadian Adverse Reaction Newsletter 14(4): 1-2 (2004).
15. C. Regnard and A. Pelham. Severe respiratory depression and sedation with transdermal fentanyl: four case studies. Palliat. Med. 17: 714-716 (2003).
16. E.M. Koves and J. Wells. An evaluation of fused silica capillary columns for the screening of basic drugs in postmortem blood: qualitative and quantitative analysis. J. Forensic Sci. 30(3): 692-707 (1985).
17. R.K. Portenoy, M.A. Southam, S.K. Gupta, J. Lapin, M. Layman, C.E. Inturrisi, and K.M. Foley. Transdermal fentanyl for cancer pain. Anesthesiology 78: 36-43 (1993).
18. D.J. Duthie, D.J. Rowbotham, R. Wyld, P.D. Henderson, and W.S. Nimmo. Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Br. J. Anaesth. 60: 614-618 (1988).
19. C.P. Bleeker, R.C. Bremer, D.A. Dongelmans, R.T. van Dongen, and B.J. Crul. Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report. Eur. J. Pain 5(3): 325-331 (2001).
20. J.C. Garriott, R. Rodriguez, and V.J. Maio. A death from fentanyl overdose. J. Anal. Toxicol. 8(6): 288-289 (1984).
21. E.M. Pare, J.R. Monforte, R. Gault, and H. Mirchandani. A death involving fentanyl. J. Anal. Toxicol. 11: 272-275 (1987).
22. R.J. Matejczyk. Fentanyl related overdose. J. Anal. Toxicol. 12(4): 236-238 (1988).
23. A.K. Chaturvedi, N.G. Rao, and J.R. Baird. A death due to self-administered fentanyl. J. Anal. Toxicol. 14(6): 385-387 (1990).
24. K.L. Woodall, T.L. Martin, and B.A. McLellan. Postmortem blood concentrations following the oral ingestion of transdermal fentanyl patches (Duragesic®). Proceedings of the American Academy of Forensic Sciences 58th Annual Meeting. Volume XII. Seattle, WA, 2006, p 361.
25. M. Purucker and W. Swann. Potential for Duragesic patch abuse. Ann. Emerg. Med. 35(3): 314-315 (2000).
26. J.L. Weemhoff, L.L. von Moltke, R. Clemens, L.M. Hesse, J.S. Harmatz, and D.J. Greenblatt. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J. Pharm. Pharmacol. 55: 381-386 (2003).
27. K.T. Olkkola, V.J. Palkama, and P.J. Neuvonen. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 91: 681-685 (1999).
28. T. Tateishi, Y. Krivoruk, Y-F. Ueng, A.J.J. Wood, F.P. Guengerich, and M. Wood. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth. Analg. 82: 167-172 (1996).
29. Janssen-Ortho, Inc. Product Monograph: Duragesic® 25, Duragesic® 50, Duragesic® 75, Duragesic® 100 - fentanyl transdermal system. Markham, ON, Canada, 2004.